Old Web
English
Sign In
Acemap
>
authorDetail
>
Kim M. Knudsen
Kim M. Knudsen
Genmab
Medicine
Clinical endpoint
Cutaneous T-cell lymphoma
Refractory
Immunology
4
Papers
305
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial.
2021
Diabetes Care
Thomas R. Pieber
Ronnie Aronson
Ulrike Hövelmann
Julie Willard
Leona Plum-Mörschel
Kim M. Knudsen
Benedikte Bandak
Ramin Tehranchi
Show All
Source
Cite
Save
Citations (6)
refractory cutaneous T-cell lymphoma Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in
2013
Steen Lisby
Ole Baadsgaard
Tim Illidge
T. Schwarz
Roland Kaufmann
Kevin Cooper
Kim M. Knudsen
Youn H. Kim
Madeleine Duvic
Erik Obitz
Robert Gniadecki
Lars Iversen
Show All
Source
Cite
Save
Citations (0)
IL-8 as antibody therapeutic target in inflammatory diseases: Reduction of clinical activity in palmoplantar pustulosis
2008
Journal of Immunology
Lone Skov
Frank Beurskens
Claus Zachariae
Sakari Reitamo
Jessica L. Teeling
David Satijn
Kim M. Knudsen
Elmieke Pj Boot
Debra Hudson
Ole Baadsgaard
Paul W. H. I. Parren
Jan G. J. van de Winkel
Show All
Source
Cite
Save
Citations (119)
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
2007
Blood
Youn H. Kim
Madeleine Duvic
Erik Obitz
Robert Gniadecki
Lars Iversen
Anders Österborg
Sean Whittaker
Tim Illidge
T. Schwarz
Roland Kaufmann
Kevin D. Cooper
Kim M. Knudsen
Steen Lisby
Ole Baadsgaard
Susan J. Knox
Show All
Source
Cite
Save
Citations (180)
1